Skip to content
Menu
  • About Us
    • About Us
    • Staff
    • District Leadership
  • Membership
  • Advocacy
    • 2024 Memos of Support
      • Topical Fluoride Varnish
      • Early Intervention Costs
      • SAFE for Kids Act
      • Lockdown Drills in Schools
      • Gender Affirming Care
      • Telehealth in Schools
    • 2023 Policy, Budget & Practice Priorities
    • 2023 Memos of Support
      • ATV Safety & Minors
      • G6PD Testing
      • Birds and Bees Protection Act
      • Informed Consent Act
      • Lead Pipe Right to Know
      • Minor Consent
      • Predatory Marketing Prevention
      • Create a Tobacco-Free Generation in NY State
      • Transgender Treatment Protection Act
      • Working Families Tax Credit
      • Lockdown Drills in Schools
    • Policy Statements
      • Statement on Israel-Gaza Conflict
      • COVID Immunization
      • COVID Vaccine for Children
      • Support – Reopening Schools
        • Reopening Schools Press Release
      • Climate Change
      • Anti-Racism Statement
      • Adult Marijuana Statement
    • 2022 Legislative Priorities
    • Advocacy Alerts & Updates
      • Advocacy Update January 2022
    • Advocacy Recent
      • 2022 Budget, Policies and Practical Issues
      • 2022 Memos of Support
        • Continuous Medicaid Coverage for Children 0-3
        • Runaway & Homeless Youth Rights to Medical Consent
        • Cumulative Environmental Impact Addressing Environmental/Health Equity
    • Archive Past
      • Value Based Primary Care Letter
      • Priority Practice Issues
      • Immigration
        • Lettter to Gov. Cuomo
        • Letter to Mayor deBlasio
      • Impact of Poverty on Children
      • Update on Hydrofracking
      • News and Notes
      • Advocacy Archives
  • Resources
    • Pediatricians (All)
      • AAP Resolutions
        • Top Ten Resolutions from the 2022 Leadership Conference
        • Resolutions Archive
          • Resolutions – 2021 Top Resolutions
          • Resolutions from the 2019 ALF
          • Resolutions from the 2018 ALF
      • CATCH
      • Project TEACH
        • Mental Health Support Services
      • AAP’s Bright Futures Guidelines
      • Immunizations for Physicians
        • Inventory Requirements for COVID-19 Vaccine and Nirsevimab
      • Recorded Webinars
      • Research
        • PROS
      • District Chair Letters
    • Pediatricians in NYC
    • Runaway and Homeless Youth
    • Pediatric Trainees & Early Career Physicians
    • Cannabis Usage
    • Parent’s Resources
  • Calendar

New York State American Academy of Pediatrics (District II)

A coalition of AAP NY Chapters 1, 2 & 3

Donate Now

Inventory Requirements for COVID-19 Vaccine and Nirsevimab

On Behalf Of doh.sm.NY.Vaccines.for.Children
Sent: Friday, October 27, 2023 9:27 AM
To: doh.dl.NYS_DOH_VFC-L <NYS_DOH_VFC-L@listserv.health.state.ny.us>
Subject: VFC Policy Flexibility on Private Inventory Requirements for COVID-19 vaccine and nirsevimab
Importance: High

Dear Vaccines for Children Provider:

CDC has announced updated Vaccines for Children (VFC) program policy flexibilities, which will allow VFC providers temporary flexibility to meet the private inventory requirements for nirsevimab and COVID-19 vaccine. During this time, the VFC program will not require VFC providers to meet the private inventory requirements for nirsevimab or COVID-19 vaccine. VFC providers are required to meet the private inventory requirement no later than March 31, 2024, for COVID-19 vaccine and August 1, 2024, for nirsevimab.

While VFC providers are not required to meet the private inventory requirements for nirsevimab and COVID-19 vaccine during this time-limited ramp-up period, New York State encourages providers to prioritize purchasing of COVID-19 vaccine for children under five years of age when possible.  Pharmacists in New York State are only authorized to administer COVID-19 vaccines to children 3 years of age and older, and many pharmacies are even more restrictive in the ages they serve.  Many local health departments do not have the capacity to contract with private health insurance plans, so cannot vaccinate privately insured patients.  The medical home is the best place for young children to receive vaccinations.   

Finally, CDC is aware from the manufacturer of the nirsevimab product that there are already supply and demand issues in the nirsevimab pipeline this season.  This will make maintaining private stock even more challenging for some providers, meaning this temporary policy change is even more relevant for RSV this season.  

We hope these policies provide additional flexibility for immunization programs as we enter this respiratory season.

Thank you for your continued commitment to the Vaccines for Children program.

If you have any questions, please email NYVFC@health.ny.gov.

Thank you.

New York State Vaccine Program

ESP Corning Tower

Albany, NY 12237

Upcoming Events

Sep
26
Fri
all-day 2025 NCE in Denver
2025 NCE in Denver
Sep 26 – Sep 30 all-day
2025 NCE in Denver
JOIN US IN DENVER! September 26–30, 2025 The AAP National Conference & Exhibition is the largest gathering of pediatric health care professionals in the world, offering a remarkable opportunity to unite in their unwavering commitment[...]
View Calendar
Add
  • Add to Timely Calendar
  • Add to Google
  • Add to Outlook
  • Add to Apple Calendar
  • Add to other calendar
  • Export to XML

© New York State American Academy of Pediatrics (District II) 2025. Powered by WordPress